Bob Lutz
Chief Scientific Officer Iksuda Therapeutics
Bob Lutz is a recognized leader in the development of ADCs, with a proven record of advancing breakthrough oncology therapeutics. Since 2015, he has advised biotech and pharma companies worldwide and currently serves as Chief Scientific Officer at Iksuda Therapeutics. Over his 23-year career at ImmunoGen, Inc., he held senior R&D leadership roles, including Vice President of Translational R&D, and played pivotal roles in the development of two FDA-approved ADCs—Kadcyla® and Elahere®.
Seminars
- Understanding the 2026 ADC landscape and how the bar has been raised to develop and deliver differentiated ADCs with meaningful patient impact
- Assessing the need for novel ADC chemistry innovation: What is showing the most promise across novel payloads and conjugation technologies?
- Discussing the potential of novel ADC biology approaches across bispecific targeting and antibody engineering to unlock next generation ADC therapies
- Highlighting methods to best pursue ADC clinical differentiation across patient selections methods, combination strategies, and well executed clinical design
- Highlighting the strategic need for diversified payload platforms to drive sustainable ADC pipeline growth and maintain market competitiveness
- Positioning protein alkylation as a differentiated and emerging modality within the evolving ADC payload landscape
- Showcasing the unique mechanism of action and therapeutic potential of Iksuda Therapeutics’ ProAlk™ payload
As an increasingly diverse array of ADCs containing different payloads and linkers are developed to tackle different tumour targets, understanding how bioconjugate design contributes and accumulates to performance, especially in the clinic, is vital to set up your therapy for success
Take part in this workshop exploring case-study examples to contextualise and understand the performance of different ADC designs to understand what really makes a clinically effective ADC
Workshop highlights include:
- Accurately correlating and characterising antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
- Delving into ADC clinical case studies to understand differentiated design impact on clinical safety and efficacy profiles
- Finding the right match: optimising ADC design to optimise payload target pairing
